Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

Related Articles by Review for PubMed (Select 12134369)

1.

Positron emission tomography in thyroid cancer management.

Larson SM, Robbins R.

Semin Roentgenol. 2002 Apr;37(2):169-74. Review.

PMID:
12134369
2.

Positron emission imaging of head and neck cancer, including thyroid carcinoma.

Schöder H, Yeung HW.

Semin Nucl Med. 2004 Jul;34(3):180-97. Review.

PMID:
15202100
3.

Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.

Nanni C, Rubello D, Fanti S, Farsad M, Ambrosini V, Rampin L, Banti E, Carpi A, Muzzio P, Franchi R.

Biomed Pharmacother. 2006 Sep;60(8):409-13. Epub 2006 Aug 1. Review.

PMID:
16891093
4.

Positron emission tomography of the thyroid, with an emphasis on thyroid cancer.

McDougall IR, Davidson J, Segall GM.

Nucl Med Commun. 2001 May;22(5):485-92. Review.

PMID:
11388568
5.

PET imaging in differentiated thyroid cancer: where does it fit and how do we use it?

Hall NC, Kloos RT.

Arq Bras Endocrinol Metabol. 2007 Jul;51(5):793-805. Review.

6.
7.

Review. 18F-FDG PET in the diagnosis and follow-up of thyroid malignancy.

Al-Nahhas A, Khan S, Gogbashian A, Banti E, Rampin L, Rubello D.

In Vivo. 2008 Jan-Feb;22(1):109-14. Review.

8.

[Utility of positron emission tomography with fluorodeoxyglucose (FDG-PET) in the evaluation of thyroid cancer: a systematic review].

Kuba VM, Caetano R, Coeli CM, Vaisman M.

Arq Bras Endocrinol Metabol. 2007 Aug;51(6):961-71. Review. Portuguese.

9.

Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.

Facey K, Bradbury I, Laking G, Payne E.

Health Technol Assess. 2007 Oct;11(44):iii-iv, xi-267. Review.

10.

FDG-PET in thyroid cancer.

Crippa F, Alessi A, Gerali A, Bombardieri E.

Tumori. 2003 Sep-Oct;89(5):540-3. Review. Erratum in: Tumori. 2004 May-Jun;90(3):366.

PMID:
14870781
11.

FDG PET and alternative imaging in the management of thyroid carcinoma.

Al-Nahhas AM.

Nucl Med Rev Cent East Eur. 2003;6(2):139-45. Review.

PMID:
14737730
12.

Positron emission tomography for prostate, bladder, and renal cancer.

Schöder H, Larson SM.

Semin Nucl Med. 2004 Oct;34(4):274-92. Review.

PMID:
15493005
13.

Value of FDG PET in the management of NSCLC.

Ukena D, Hellwig D.

Lung Cancer. 2004 Aug;45 Suppl 2:S75-8. Review.

PMID:
15552785
14.

PET and PET-CT for evaluation of colorectal carcinoma.

Delbeke D, Martin WH.

Semin Nucl Med. 2004 Jul;34(3):209-23. Review.

PMID:
15202102
15.

PET/CT imaging in recurrent head and neck cancer.

Fukui MB, Blodgett TM, Meltzer CC.

Semin Ultrasound CT MR. 2003 Jun;24(3):157-63. Review.

PMID:
12877412
16.

The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma.

Lubberink M, Abdul Fatah S, Brans B, Hoekstra OS, Teule GJ.

Q J Nucl Med Mol Imaging. 2008 Mar;52(1):30-6. Review.

PMID:
17657202
17.

Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis.

Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, Chan JK, Owens DK.

Ann Intern Med. 2003 Dec 2;139(11):879-92. Review.

PMID:
14644890
18.

The value of positron emission tomography (PET) in the management of patients with thyroid cancer.

Robbins RJ, Larson SM.

Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):1047-59. doi: 10.1016/j.beem.2008.10.001. Review.

PMID:
19041831
19.

Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ.

Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S48-56. doi: 10.1007/s00259-011-1773-5. Epub 2011 Apr 12. Review.

PMID:
21484380
20.

Molecular imaging in the management of thyroid cancer.

Wong KK, Dvorak RA, Marzola MC, Grassetto G, Gross MD, Rubello D.

Q J Nucl Med Mol Imaging. 2011 Oct;55(5):541-59. Review.

PMID:
22019711
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk